All Updates

All Updates

icon
Filter
Funding
Generate Biomedicines raises USD 273 million in Series C funding
AI Drug Discovery
Sep 15, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Sep 15, 2023

Generate Biomedicines raises USD 273 million in Series C funding

Funding

  • AI drug development company Generate Biomedicines has raised USD 273 million in a Series C funding round led by Amgen, with participation from NVentures, MAPS Capital, Pictet Alternative Advisors, and other existing investors. This brings the total fund raised by the company to USD 693 million.

  • The funds will support the advancement of the company’s pipeline of protein therapies, enhance its generative biology platform, pursue collaborations, and invest in new program starts. The company plans to file a Clinical Trial Application for its anti-TSLP monoclonal antibody by early Q4 2023 and initiate multiple clinical trials annually. In addition, Generate Biomedicines also aims to submit multiple Investigational New Drug (IND) applications in 2024.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.